Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rising-VTE PK study of edoxaban with EGFR-TKI in EGFR-mutated non-small cell lung cancer
jRCTs061180026Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of edoxaban in venous thromboembolism (VTE) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Pharmacokinetic analysis. Started Aug 2016; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061180026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180026.